Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-08-09
2011-08-09
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S631000, C514S636000
Reexamination Certificate
active
07994225
ABSTRACT:
Efflux pump inhibitors are co-administered with antimicrobial agents for the treatment of ophthalmic or otic infections. The agents may be co-administered directly to the site of infection (e.g., the eye or ear).
REFERENCES:
patent: 4324794 (1982-04-01), Tidwell et al.
patent: 4397863 (1983-08-01), Tidwell et al.
patent: 4619942 (1986-10-01), Tidwell et al.
patent: 4823784 (1989-04-01), Bordoni et al.
patent: 4853416 (1989-08-01), Anaebonam et al.
patent: 4895719 (1990-01-01), Radhakrishnan et al.
patent: 4933347 (1990-06-01), Tidwell et al.
patent: 4963589 (1990-10-01), Tidwell et al.
patent: 5049389 (1991-09-01), Radhakrishnan
patent: 5084480 (1992-01-01), Pai et al.
patent: 5089527 (1992-02-01), Lord
patent: 5162361 (1992-11-01), Rosenthal et al.
patent: 5202320 (1993-04-01), Tidwell et al.
patent: 5204113 (1993-04-01), Hartley et al.
patent: 5206236 (1993-04-01), Tidwell et al.
patent: 5262157 (1993-11-01), Bernard et al.
patent: 5334374 (1994-08-01), Hartley et al.
patent: 5355872 (1994-10-01), Riggs et al.
patent: 5364615 (1994-11-01), Debs et al.
patent: 5366726 (1994-11-01), Debs et al.
patent: 5428051 (1995-06-01), Tidwell et al.
patent: 5474759 (1995-12-01), Fassberg et al.
patent: 5485827 (1996-01-01), Zapol et al.
patent: 5521189 (1996-05-01), Boykin et al.
patent: 5534496 (1996-07-01), Lee et al.
patent: 5556637 (1996-09-01), Hager et al.
patent: 5597573 (1997-01-01), Kamireddy et al.
patent: 5602172 (1997-02-01), Boykin et al.
patent: 5606058 (1997-02-01), Boykin et al.
patent: 5622955 (1997-04-01), Boykin et al.
patent: 5627184 (1997-05-01), Boykin et al.
patent: 5668166 (1997-09-01), Tidwell et al.
patent: 5668167 (1997-09-01), Tidwell et al.
patent: 5674911 (1997-10-01), Emanuele et al.
patent: 5686456 (1997-11-01), Boykin et al.
patent: 5723495 (1998-03-01), Hall et al.
patent: 5725871 (1998-03-01), Illum
patent: 5741517 (1998-04-01), Hager et al.
patent: 5770585 (1998-06-01), Kaufman et al.
patent: 5843980 (1998-12-01), Hall et al.
patent: 5869091 (1999-02-01), Carter et al.
patent: 5873359 (1999-02-01), Zapol et al.
patent: 5989832 (1999-11-01), Trias et al.
patent: 6008247 (1999-12-01), Boykin et al.
patent: 6025398 (2000-02-01), Hall et al.
patent: 6076522 (2000-06-01), Dwivedi et al.
patent: 6098619 (2000-08-01), Britto et al.
patent: 6114310 (2000-09-01), Chamberland et al.
patent: 6123924 (2000-09-01), Mistry et al.
patent: 6126919 (2000-10-01), Stefely et al.
patent: 6127554 (2000-10-01), Boykin et al.
patent: 6172104 (2001-01-01), Tidwell et al.
patent: 6180604 (2001-01-01), Fraser et al.
patent: 6204279 (2001-03-01), Leger et al.
patent: 6214883 (2001-04-01), Hall et al.
patent: 6245746 (2001-06-01), Chamberland et al.
patent: 6309623 (2001-10-01), Weers et al.
patent: 6326395 (2001-12-01), Tidwell et al.
patent: 6346391 (2002-02-01), Oethinger et al.
patent: 6362229 (2002-03-01), Markham et al.
patent: 6399629 (2002-06-01), Chamberland et al.
patent: 6416742 (2002-07-01), Stefely et al.
patent: 6423737 (2002-07-01), Hall et al.
patent: 6436980 (2002-08-01), Leger et al.
patent: 6486200 (2002-11-01), Boykin et al.
patent: 6503881 (2003-01-01), Krieger et al.
patent: 6503940 (2003-01-01), Boykin et al.
patent: 6538106 (2003-03-01), Fraser et al.
patent: 6553987 (2003-04-01), Davies
patent: 6613787 (2003-09-01), Wilson et al.
patent: 6635668 (2003-10-01), Tidwell et al.
patent: 6641800 (2003-11-01), Mistry et al.
patent: 6649652 (2003-11-01), Boykin et al.
patent: 6677133 (2004-01-01), Oethinger et al.
patent: 6720003 (2004-04-01), Chen et al.
patent: 7026136 (2006-04-01), Oethinger et al.
patent: 7037495 (2006-05-01), Burnie et al.
patent: 7056917 (2006-06-01), Nakayama et al.
patent: 0345926 (1991-08-01), None
patent: 0309519 (1992-07-01), None
patent: 0383680 (1992-12-01), None
patent: WO 96/40117 (1996-12-01), None
patent: WO 99/37667 (1999-07-01), None
patent: WO 02/09758 (2002-02-01), None
Definition of prevent, Oxford English Dictionary, http://dictionary.oed.com/, accessed online on May 27, 2010.
Shepp et al. J. Acquired Immune Deficiency Syndromes, 1994, 7(8), p. 823-831.
Dropulic et al. J. Infectious Diseases, 1995, 171(4), p. 930-937.
Anne, et al., “Antifungal and antibacterial activities of diarylamidine derivatives,”Antimicrobial Agents and Chemotherapy, 18(2), 231-9.
Baucheron, et al., “The AcrB Multidrug Transporter Plays a Major Role in High-Level Fluoroquinolone Resistance inSalmonella entericaSerovar Typhimurium Phage Type DT204,”Microbial Drug Resistance, vol. 8, 2002, 281-289.
Bichowsky-Slomnitzki L, “Inhibitory Action of Diamidines and Stimulative Effect of Polyamines on Enzymatic Activites ofEscherichia coliandMicrococcus aureus,” Arch. Biochem., Jul. 1950, 27(2):294-303.
Bichowsky-Slomnitzki L, “The Effect of Aromatic Diamidines on Bacterial Growth,”J. Bact. 1948, 55:27-31.
Chauhan, et al., “Synthesis of 2,7-diamidinoxanthone, thioxanthone and related compounds as potential leishmanicides,”Indian J. of Chem., Section B: Organic Chemistry Including Medicinal Chemistry, 26B(3), 248-50.
Dave R., et al. Amino Acids, 24, 2003, 245-261.
Delia, et al., “Ring-based analogues of pentamidine versusP. cariniipneumonia in culture,”Bioorganic&Medicinal Chemistry Letters, 1996, vol. 6, 2367-2370.
Donkor IO et al., “In vitro antimicrobial activity of aromatic diamidines and diimidazolines related to pentamidine,”Eur. J. Med. Chem. 34 (1999) 639-643.
Donkor, et al., “Trypanocidal Activity of Conformationally Restricted Pentamidine Congeners,”J. Med. Chem., (2003) 46, 1041-1048.
Donkor, et al., “In vitro antimicrobial activity of aromatic diamidines and diimidazolines related to pentamidine,”Eur. J. Med. Chem. (1999) 34, 639-643.
Donkor, et al., “Pentamidine Congeners. 2. 2-Butene-Bridged Aromatic Diamidines and Diimidazolines as Potential Anti-Pneumocystis cariniiPneumonia Agents,”J. Med. Chem. 1994, 37, 4554-4557.
Feddersen, A., et al., “Experimental studies on the nephrotoxicity of pentamidine in rats,”Journal of Antimicrobial Chemotherapy, 1991, 28, 437-446.
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10thEdition, McGraw-Hill Medical Publishing Division, 2001, pp. 54-56.
Helweg-Larsen et al., “Pneumocystic carniiPneumonia,”Current Treatment Options in Infectious Diseases, (2002) 4:363-375.
Hicks, MR, “The Effect of Isoniazid, Carbutamide, Propamidine and Pentamidine on the Transaminases and Growth ofEscherichia coli, Strain 15, Mutant M2,”Biochimica Et Biophysica Acta, 1961, 46:143-151.
Hsieh P-C et al., “Bacteria lacking a multidrug pump: A sensitive tool for drug discovery,”Proc. Natl. Acad. Sci., Jun. 1998, 95:6602-6606.
International Search Report and Written Opinion from International Application No. PCT/US2005/008873, mailed Jun. 26, 2007.
Invitation to Pay Additional Fees dated Mar. 2, 2007, received in International Application No. PCT/US2005/008873.
Jennings, F.W., “Effect of Tetracycline Administration on the Efficacy of Diminazene Aceturate Therapy . . . ”,Research in Veterinary Science, 1987, 43, pp. 173-176.
Jones, et al., “Novel Pentamidine Analogs in the Treatment of ExperimentalPneumocystis cariniiPneumonia,”Antimicrobial Agents and Chemotherapy, Jun. 1990, pp. 1026-1030.
Kaatz, “Inhibition of bacterial efflux pumps: a new strategy to combat increasing antimicrobial agent resistance,”Expert Opin. Emerging Drugs 7(2002) 223-233.
Kohn HI, “The Effect of Propamidine on Bacterial Growth,”Science, 98(2540):224.
Levy, “Active Efflux Mechanisms for Antimicrobial Resistance,”Antimicrobial Agents and Chemotherapy, 36(4), 695-703.
Lewis JD et al., “Cephalosporin-pentamidine isethionate incompatibilities,”Am. J. Health-Syst. Pharm., Jun. 15, 1996, 53:1461-1462.
Libman, “Antistaphylococcal Activity of Pentamidine,”Antimicrobial Agents and Chemotherapy, Sep. 1990, 1795-1796.
Lomovskaya, et al., “Identification and
Berkley Neil
Bostian Keith
Glinka Tomasz
Griffith David
Lomovskaya Olga
Jiang Shaojia Anna
Knobbe Martens Olson & Bear LLP
Lau Jonathan
Rempex Pharmaceuticals, Inc.
LandOfFree
Bacterial efflux pump inhibitors for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bacterial efflux pump inhibitors for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bacterial efflux pump inhibitors for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2623372